Keywords: Roche, Zelboraf, Metastatic melanoma, Daiichi Sankyp, European approval

European approval for Roche skin cancer drug Zelboraf

Article | 21 February 2012

Print This

Swiss drug major Roche (ROG: SIX) says that the European Commission has approved Zelboraf (vemurafenib) as a monotherapy for the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in